1
|
Alain CB, Antoine LK, Bizette BN, Dahlia P, Dophie TB, Jérémie MM, Donatien KNN, Steve AM. The human parvovirus B19/human immunodeficiency virus co-infection in healthy eligible voluntary blood donors at the Blood Transfusion National Center in Kinshasa. Pan Afr Med J 2020; 35:69. [PMID: 32523647 PMCID: PMC7255965 DOI: 10.11604/pamj.2020.35.69.21018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Accepted: 02/19/2020] [Indexed: 11/11/2022] Open
Abstract
Introduction Parvovirus B19 (PVB19) is one of several viruses transmissible by blood transfusion. Levels of exposure to PVB19 among HIV-infected voluntary blood donors are comparable to those among HIV-negative controls because, in blood donors, the PVB19 infection is transmitted mainly via the respiratory route. Thus, we hypothesize that the seroprevalence of PVB19 in HIV-positive blood donors is equal to the seroprevalence of PVB19 in HIV-negative blood donors. The objective of this study was to compare the seroprevalence of PVB19 between asymptomatic HIV-positive and HIV-negative blood donors. Methods A random sample of 360 eligible blood donors were firstly examined for HIV antibodies by using ELISA automaton and so were categorized as HIV-positive donors and HIV-negative donors. Then the two categories of donors were examined for PVB19 IgG and IgM by using ELISA kits. The seroprevalence of PVB19 in HIV-positive donors was compared to that of HIV-negative donors by using chi-square test or Fisher's exact test. All statistical analyzes were performed with SPSS 21. Results The prevalences of PVB19 IgG and IgM in HIV-positive blood donors were 92.1% (35 of 38) and 44.7% (17 of 38), respectively and those in control group were 89.1% (287 of 322) and 46.3% (149 of 322), respectively. But for both IgG and IgM the difference was not statistically significant (p > 0.05). Conclusion This research confirms our hypothesis: the seroprevalence of PVB19 in HIV-positive blood donors is equal to the seroprevalence of PVB19 in HIV-negative blood donors.
Collapse
Affiliation(s)
- Chabo Byaene Alain
- Department of Immunology and Regenerative Medicine, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.,Department of Medical Biology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Lufimbo Katawandja Antoine
- Department of Medical Biology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Bizeti Nsangu Bizette
- Department of Medical Biology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Pambu Dahlia
- Department of Medical Biology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Tshibuela Beya Dophie
- Department of Medical Biology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | - Muwonga Masidi Jérémie
- Department of Medical Biology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| | | | - Ahuka Mundeke Steve
- Department of Medical Biology, Faculty of Medicine, University of Kinshasa, Kinshasa, Democratic Republic of Congo
| |
Collapse
|
2
|
Pedranti MS, Rodriguez-Lombardi G, Bracciaforte R, Romano N, Lujan P, Ricchi B, Mautino J, Adamo MP. Parvovirus B19 in HIV+ adult patients with different CD4+ lymphocyte counts. J Med Microbiol 2017; 66:1715-1721. [PMID: 29095139 DOI: 10.1099/jmm.0.000629] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
PURPOSE Human parvovirus B19 (B19V) can cause anemia in immunocompromised patients. We aimed to investigate the presence of B19V in HIV+ adults with different CD4+ T cell counts, to recognise the frequency of B19V in these different conditions and its possible association with anemia. METHODOLOGY We studied B19V specific IgM, IgG and DNA in 98 HIV+ patients and in 52 healthy individuals. HIV load, CD4+ counts and haemoglobin level were also determined in the patients. RESULTS No individual in the control group had detectable IgM, 41/52 (78.8 %) had IgG and 5/52 (9.6 %) had B19V DNA. Among HIV+ patients, we found 5/98 (5.1 %) IgM+, 66/98 (67.3 %) IgG+ and 15/98 (15.3 %) had B19V DNA (no significant differences between the two groups compared). Considering the CD4+ cell range in HIV patients, 37 had <200 CD4+ cells ml-1, 31 had 200-500, and 30 had >500. Anti-B19V IgG prevalence in patients with >500 CD4+ cells ml-1 was significantly higher than in the rest (P=0.004) and compared to the control (P=0.046). B19V DNA concentration was always <103 IU ml-1, including 5 healthy individuals and 15 HIV+ patients. There was no significant association between B19V IgM or DNA and anemia nor between B19V DNA and HIV load. CONCLUSIONS The results indicate that B19V is not a high-risk factor for anemia in adult HIV+ patients under HAART treatment. Further studies will contribute to elucidate the mechanisms and significance of B19V DNA prevalence/persistence in adults, independently of the CD4+ cell status.
Collapse
Affiliation(s)
- Mauro Sebastian Pedranti
- Institutode Virología 'Dr J. M. Vanella', Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina.,Fundaciónpara el Progreso de la Medicina, Córdoba, Argentina
| | | | - Romina Bracciaforte
- Institutode Virología 'Dr J. M. Vanella', Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| | | | - Pablo Lujan
- Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina
| | - Brenda Ricchi
- Hospital Privado, Centro Médico de Córdoba, Córdoba, Argentina
| | - Jorge Mautino
- Fundaciónpara el Progreso de la Medicina, Córdoba, Argentina
| | - Maria Pilar Adamo
- Institutode Virología 'Dr J. M. Vanella', Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
| |
Collapse
|
3
|
Abstract
Parvovirus B19 (B19V) and human bocavirus 1 (HBoV1), members of the large Parvoviridae family, are human pathogens responsible for a variety of diseases. For B19V in particular, host features determine disease manifestations. These viruses are prevalent worldwide and are culturable in vitro, and serological and molecular assays are available but require careful interpretation of results. Additional human parvoviruses, including HBoV2 to -4, human parvovirus 4 (PARV4), and human bufavirus (BuV) are also reviewed. The full spectrum of parvovirus disease in humans has yet to be established. Candidate recombinant B19V vaccines have been developed but may not be commercially feasible. We review relevant features of the molecular and cellular biology of these viruses, and the human immune response that they elicit, which have allowed a deep understanding of pathophysiology.
Collapse
Affiliation(s)
- Jianming Qiu
- Department of Microbiology, Molecular Genetics and Immunology, University of Kansas Medical Center, Kansas City, Kansas, USA
| | | | - Neal S Young
- Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Maryland, USA
| |
Collapse
|
4
|
Zhang L, Cai C, Pan F, Hong L, Luo X, Hu S, Xu J, Chen Z. Epidemiologic study of human parvovirus B19 infection in East China. J Med Virol 2016; 88:1113-9. [PMID: 26705119 DOI: 10.1002/jmv.24459] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 12/22/2015] [Indexed: 12/16/2022]
Abstract
Human parvovirus B19 (B19V) infection causes a number of diseases in humans, and, in some circumstances, can be life threatening. To understand the epidemiology of B19V infection in the greater metropolitan area of Hangzhou, East China, we performed surveys of IgM and IgG antibodies against B19V and quantification of B19V DNA, by using enzyme-linked immunosorbent assay and quantitative PCR, respectively, in plasma samples from diverse groups. These groups included anemia patients, Mycoplasma pneumonia- and Treponema pallidum-infected patients, HIV-positive individuals, and healthy blood donor volunteers. Our results demonstrated a low level of B19V IgG antibody presence, ranging from 21.9% to 41.8% in all the groups tested, suggesting a low prevalence of B19V infection in the area. Of note, we found that two healthy blood donors and one Mycoplasma pneumonia-infected patient had B19V IgM antibody among 1,290 plasma samples tested. The Mycoplasma pneumonia-infected patient had viremia with viral genome copies of 2.86 × 10(6) per ml of plasma. We detected a high rate of B19V DNA (7.1%) in HIV-positive injection drug users. Importantly, an amino acid mutation of P558S in the large non-structural protein NS1 was identified to be conserved among 14 B19V isolates from the HIV-positive group but not in the B19V isolate of the Mycoplasma pneumonia-infected patient, representing a hallmark of B19V isolates that circulate in HIV1-positive patients in the greater metropolitan area of Hangzhou, East China.
Collapse
Affiliation(s)
- Lahong Zhang
- The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
| | - Chengsong Cai
- The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
| | - Feng Pan
- The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
| | - Liquan Hong
- The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
| | - Xian Luo
- The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
| | | | - Jiali Xu
- The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
| | - Zhaojun Chen
- The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China
| |
Collapse
|
5
|
Sterpu R, Ichou H, Mahé I, Mortier E. [Reactivation of parvovirus B19 infection in an HIV-infected woman]. Rev Med Interne 2013; 35:396-8. [PMID: 23791089 DOI: 10.1016/j.revmed.2013.05.009] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2013] [Revised: 04/30/2013] [Accepted: 05/07/2013] [Indexed: 10/26/2022]
Abstract
INTRODUCTION Infection by human parvovirus B19 (erythrovirus B19) is common and usually asymptomatic during childhood conferring lasting protection against a new infection. Parvovirus B19 infection may cause erythema infectiosum (5th disease) and aplastic crisis. Secondary symptomatic parvovirus B19 infection in the same patient is rare and its physiopathology is not always clear. CASE REPORT A 48-year-old HIV-infected female patient presented within 5 years two acute episodes of parvovirus B19 infection although her CD4 cells count was above 500/mm(3). Absence of specific antibodies production after the first episode and persisting parvovirus viremia suggested viral reactivation rather than re-infection. During the second episode, specific antibodies were produced. CONCLUSION Similarly to most DNA viruses, parvovirus B19 reactivation is possible in HIV-infected patients while effectively treated by antiretroviral therapy.
Collapse
Affiliation(s)
- R Sterpu
- Service de médecine interne, hôpital Louis-Mourier (AP-HP), 178, rue des Renouillers, 92700 Colombes, France
| | - H Ichou
- Service de microbiologie, hôpital Louis-Mourier (AP-HP), 178, rue des Renouillers, 92700 Colombes, France
| | - I Mahé
- Service de médecine interne, hôpital Louis-Mourier (AP-HP), 178, rue des Renouillers, 92700 Colombes, France
| | - E Mortier
- Service de médecine interne, hôpital Louis-Mourier (AP-HP), 178, rue des Renouillers, 92700 Colombes, France.
| |
Collapse
|
6
|
Azevedo KMLD, Setúbal S, Camacho LAB, Garcia RDCNC, Siqueira MM, Pereira RFA, Oliveira SAD. Parvovirus B19 seroconversion in a cohort of human immunodeficiency virus-infected patients. Mem Inst Oswaldo Cruz 2012; 107:356-61. [DOI: 10.1590/s0074-02762012000300010] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2011] [Accepted: 01/11/2012] [Indexed: 11/21/2022] Open
|
7
|
Azevedo KMLD, Setúbal S, Camacho LAB, Velarde LGC, Oliveira SAD. Seroepidemiological study of human parvovirus B19 among human immunodeficiency virus-infected patients in a medium-sized city in Rio de Janeiro, Brazil. Mem Inst Oswaldo Cruz 2010; 104:901-4. [PMID: 19876564 DOI: 10.1590/s0074-02762009000600014] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/27/2009] [Accepted: 07/22/2009] [Indexed: 11/22/2022] Open
Abstract
Parvovirus B19 (B-19) may cause chronic anaemia in immunosuppressed patients, including those infected with human immunodeficiency virus (HIV). We studied single serum samples from 261 consecutive HIV-infected patients using an enzyme immunoassay to detect IgG antibodies to B-19. The seroprevalence of B-19-IgG was 62.8%. The differences in seroprevalence across gender, age, educational categories, year of collection of the serum samples, clinical and antiretroviral therapy characteristics, CD4+ count, CD4+ and CD8+ percentage and CD4+/CD8+ ratios were neither substantial nor statistically significant. There was a non-significant, inverse association between B-19 seropositivity and plasma HIV load and haemoglobin level. Our results indicated that 37.1% of patients might be susceptible to B-19 infection and remained at risk for being infected, mainly during epidemic periods. As B-19 infection can be treated with immune globulin preparations, it may be included in the diagnostic approach toward chronic anaemia in HIV-infected patients.
Collapse
Affiliation(s)
- Kátia Martins Lopes de Azevedo
- Disciplina de Doenças Infecciosas e Parasitárias, Hospital Universitário Antônio Pedro, Universidade Federal Fluminense, Niterói, RJ, Brasil.
| | | | | | | | | |
Collapse
|
8
|
Affiliation(s)
- R D Semba
- Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
| | | |
Collapse
|